文献速递胸部肿瘤放疗

立体定向放疗推量治疗II/III期非小细胞肺癌放化疗后残留病变的前瞻性研究长期随访更新

Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-07-29

该前瞻性研究报道了对IIB/III期非小细胞肺癌患者放化疗后氟脱氧葡萄糖正电子发射断层扫描阳性的残留病灶(≤5 cm)进行立体定向放疗推量(10 Gy×2次或6.5 Gy×3次,总生物等效剂量>100 Gy)的长期结局。中位随访25.2个月,全组粗局部控制率为78%,中位总生存期为25.2个月,中位无进展生存期为6个月;未观察到额外的晚期毒性。

要点

  • 放化疗后对残留病灶进行立体定向放疗推量安全,局部控制率78%。
  • 中位总生存期25.2个月,鳞癌患者总生存期劣于其他病理类型。
  • IIIB期患者无进展生存期显著劣于IIB/IIA期(4.7个月 vs 9.4个月,P=.03)。

核心结论

  • 放化疗后立体定向放疗推量是安全的治疗方式,改善了局部晚期非小细胞肺癌的局部控制,未观察到额外的晚期毒性,可能改善总生存但需更大规模前瞻性试验验证。

主要发现

  • 中位随访25.2个月,全组粗局部控制率为78%(n=29),10例(29%)出现区域复发,24例(65%)出现转移。
  • 末次随访时5例(13.5%)存活且无疾病证据,27例(73%)死于疾病,5例(13.5%)死于其他原因。
  • 全组中位总生存期为25.2个月;鳞癌中位总生存期15.6个月,其他病理类型(排除大细胞神经内分泌肿瘤)为34.8个月(P=.04)。
  • 中位无进展生存期为6个月;IIB/IIA期中位无进展生存期9.4个月,IIIB期为4.7个月(P=.03)。
  • 3级肺炎的预测因素包括年龄和平均肺剂量。

关键数值与推荐

  • 残留病灶限定为原发肿瘤部位≤5 cm。
  • 立体定向放疗推量方案为10 Gy×2次或6.5 Gy×3次,总生物等效剂量>100 Gy。
  • 3级肺炎预测因素包括年龄和平均肺剂量。

临床怎么用

  • 对IIB/III期非小细胞肺癌放化疗后PET阳性残留病灶(≤5 cm)可考虑立体定向放疗推量以提高局部控制。
  • 治疗决策时需关注年龄和平均肺剂量以评估3级肺炎风险。
  • 鳞癌和IIIB期患者预后较差,应加强随访和后续治疗评估。

局限性

  • 总生存改善为可能发现,需更大规模前瞻性试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report long-term outcomes (risk of late toxicities, local control, and survival) of dose escalation by stereotactic radiation therapy boost to residual fluorodeoxyglucose positron emission tomography-positive residual disease after chemoradiation (CRT) in stage III non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Patients with stage IIB/III NSCLC underwent computed tomography or positron emission tomography-computed tomography screening approximately 1 month after completion of CRT. Limited residual disease (≤5 cm) within the site of the primary tumor received a stereotactic radiation therapy boost of either 10 Gy × 2 fractions or 6.5 Gy × 3 fractions to the primary tumor, to achieve a total Biologically Equivalent Dose >100 Gy. RESULTS: Thirty-seven patients received protocol therapy. With a median follow-up of 25.2 months, the crude local control rate for the entire group was 78% (n=29), but 10 patients (29%) and 24 patients (65%) developed regional and metastatic disease, respectively. At last follow-up, 5 patients (13.5%) remain alive, all with no evidence of disease, whereas 27 (73%) died of disease and the remaining 5 (13.5%) died of other causes. Median overall survival (OS) for the entire group was 25.2 months. Predictors for grade 3 pneumonitis included age and mean lung dose. Poorer median OS was associated with histology: median OS 15.6 months for squamous cell versus 34.8 months for other histologies (large cell neuroendocrine tumors excluded) (P=.04). The median progression-free survival was 6 months, with IIIB disease having significantly worse median progression-free survival (stages IIB/IIA being 9.4 months, vs 4.7 months for stage IIIB [P=.03]). CONCLUSIONS: Stereotactic radiation therapy boost after CRT is a safe treatment resulting in improvements in local control for locally advanced NSCLC. No additional late toxicities were seen. Possible improvement in OS was found, but further study in a larger prospective trial is needed.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kumar S, Feddock J, Li X, et al. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280459. doi:10.1016/j.ijrobp.2017.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。